Clinical Trial

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.
Protocol Amendment History 2 changes
notable Trial sites expanded: 43 -> 50 locations 2026-07-03
notable Trial sites expanded: 3 -> 43 locations 2026-04-24
Trial Details
NCT Number NCT06979323
Lead Sponsor GlaxoSmithKline
Conditions Asthma
Enrollment 150 participants
Start Date 2024-07-19
Primary Completion 2028-01-05 (estimated)
Study Completion 2028-02-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-02